Warren Huff, Reata CEO
FDA rejects Reata's kidney drug after adcomm voted unanimously against it
When an FDA adcomm unanimously votes against a drug, it’s not always guaranteed that the FDA will follow suit (e.g. Biogen’s Aduhelm). But in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
